Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns

被引:7
|
作者
Mosquera Orgueira, Adrian [1 ,2 ,3 ]
Antelo Rodriguez, Beatriz [1 ,2 ,3 ]
Alonso Vence, Natalia [1 ,2 ]
Bendana Lopez, Angeles [1 ,2 ]
Diaz Arias, Jose Angel [1 ,2 ]
Diaz Varela, Nicolas [2 ]
Gonzalez Perez, Marta Sonia [1 ,2 ]
Perez Encinas, Manuel Mateo [1 ,3 ]
Bello Lopez, Jose Luis [1 ,2 ,3 ]
机构
[1] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain
[2] Complexo Hosp Univ Santiago de Compostela, Div Hematol, SERGAS, Santiago De Compostela, Spain
[3] Univ Santiago de Compostela, Dept Med, Santiago De Compostela, Spain
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
日本学术振兴会;
关键词
chronic lymphocytic leukemia; time to treatment prediction; gene expression; RNAseq; machine learning; prognostic factors; IGHV; LYMPHOMA;
D O I
10.3389/fonc.2019.00079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome in western countries. CLL evolution is frequently indolent, and treatment is mostly reserved for those patients with signs or symptoms of disease progression. In this work, we used RNA sequencing data from the International Cancer Genome Consortium CLL cohort to determine new gene expression patterns that correlate with clinical evolution.We determined that a 290-gene expression signature, in addition to immunoglobulin heavy chain variable region (IGHV) mutation status, stratifies patients into four groups with notably different time to first treatment. This finding was confirmed in an independent cohort. Similarly, we present a machine learning algorithm that predicts the need for treatment within the first 5 years following diagnosis using expression data from 2,198 genes. This predictor achieved 90% precision and 89% accuracy when classifying independent CLL cases. Our findings indicate that CLL progression risk largely correlates with particular transcriptomic patterns and paves the way for the identification of high-risk patients who might benefit from prompt therapy following diagnosis.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Personalizing treatment for chronic lymphocytic leukemia
    Abrisqueta, Pau
    Crespo, Marta
    Bosch, Francesc
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (01) : 27 - 35
  • [32] Flavopiridol in the treatment of chronic lymphocytic leukemia
    Christian, Beth A.
    Grever, Michael R.
    Byrd, John C.
    Lin, Thomas S.
    CURRENT OPINION IN ONCOLOGY, 2007, 19 (06) : 573 - 578
  • [33] Bendamustine in the treatment of chronic lymphocytic leukemia
    Knaulf, Wolfgang
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (02) : 165 - 174
  • [34] OBINUTUZUMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    Rogers, K. A.
    Jones, J. A.
    DRUGS OF TODAY, 2014, 50 (06) : 407 - 419
  • [35] New treatments for chronic lymphocytic leukemia
    Chanan-Khan A.A.
    Current Oncology Reports, 2007, 9 (5) : 353 - 360
  • [36] New agents in chronic lymphocytic leukemia
    Robak T.
    Current Treatment Options in Oncology, 2006, 7 (3) : 200 - 212
  • [37] New Agents in Chronic Lymphocytic Leukemia
    Lin, Thomas S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2010, 5 (01) : 29 - 34
  • [38] Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
    Kost, Sara E. F.
    Saleh, Ali
    Mejia, Edgard M.
    Mostafizar, Marina
    Bouchard, Eric D. J.
    Banerji, Versha
    Marshall, Aaron J.
    Gibson, Spencer B.
    Johnston, James B.
    Katyal, Sachin
    CANCERS, 2019, 11 (10)
  • [39] Transcriptional profiling of chronic lymphocytic leukemia: is there still more to learn?
    Gartenhaus, Ronald
    LEUKEMIA & LYMPHOMA, 2009, 50 (01) : 10 - 11
  • [40] New Agents in Chronic Lymphocytic Leukemia
    Thomas S. Lin
    Current Hematologic Malignancy Reports, 2010, 5 : 29 - 34